DXS INTERNATIONAL PLC

FINAL RESULTS

The Directors of DXS International plc, the developer and supplier of clinical decision support systems to Clinical Commissioning Groups and healthcare professionals are pleased to announce the Company's Final Results for the year ending 30th April 2014.

Financial Highlights

The year under review has seen a number of significant achievements:

• Turnover increased by 26% from £1.43m to £1.81m;
• Successful Entitlement and Open Offer concluded and oversubscribed raising £433,000;
• Turnover up by 10% in Q1;

Operational Highlights

• One of only 17 companies to achieve successful conclusion of the Company's application for Lot 1 approval under the new GP Systems of Choice 2;
• 8 new CCGs ("Clinical Commissioning Groups") added bringing the total at April 2014 to 20 (843 GP practices);
• Continued R&D resulting in the market launch of DXS Triage and further enhancements to DXS Point of Care; 
• DXS awarded Preferred Supplier status by the NHS in March 2014 for Clinical Decision Support solutions to the NHS;

Commenting on the results, Chairman Bob Sutcliffe said: "We have already increased resources in sales, marketing, content, coding, support and training in anticipation of our new (and existing) client base.  With turnover up 10% in the first quarter, these are exciting times indeed for DXS International and I look forward to the future with confidence."

Contacts:

For further information please contact:
 

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings

The following information has been extracted from the Company's audited accounts for the year to 30th April 2014.

The Directors of DXS International plc accept responsibility for this announcement.

CHAIRMAN'S REPORT

Revenue grew from £1,436,317 at April 2013 to £1,815,795 at April 2014, a significant 26%. This was attributed to 8 new CCGs (Clinical Commissioning Groups) contracting with DXS in the last quarter, bringing the total as at April 2014 to 20. Since the year end, this has increased further to 22 and we are at varying stages in securing a further 14 new CCG customers. These sales are being driven by the need for CCG's, currently controlling an annual healthcare budget of £70 billion, to find savings of up to £20 billion by 2015, monies that will be re-invested within the NHS so that it can deliver year-on-year quality improvements. CCGs are increasingly realising that the DXS Clinical Decision Support solution helps them to deliver their recommended treatment guides to their clinicians - during the patient encounter and at the point of decision in a cost effective manner.

Over the last 15 months DXS' Directors and Staff have focussed on the Company's application for Lot 1 approval under the new GP Systems of Choice ("GPSoC"), part of the NHS' overall procurement structure, which was announced on March 28th of this year. GPSoC is a scheme through which the NHS funds the provision of Clinical Systems to General Practitioner (GP) practices in England, which was introduced in 2007.

The new GPSoC2 scheme, effective from 1st April 2014, was extended to include "Subsidiary Suppliers" of various IT systems. DXS was delighted to have announced that it had successfully won a bid as an approved subsidiary supplier of Clinical Decision Support to the NHS in England for GPSoC2.  This tender award runs until December 2016, but also envisages an extension for a further two years from that date.

The healthcare market demands innovation and DXS continues with a program of R&D which has added new modules to our existing Point of Care Solution all aimed at achieving reduced cost and improved quality of care. Our strategy is to partner with innovative solutions/services that we can leverage off our existing footprint wherever possible. One area of focus is chronic disease. For example, Diabetes alone consumes 10% of the UK healthcare budget and we are working with a consortium of UK clinicians to deliver a Personalised Care Pathway Solution which we hope to launch in 2015.

All GPSoC2 winners are required to meet a minimum set of requirements which are expected to evolve during the life of the contract. DXS has spent the past period putting in place the resources and systems to bring the Company to the required levels of conformance. One key area of compliance is the interface with the various GP Clinical Systems. DXS is well positioned in this respect due to existing integrations with the Clinical Systems provided by EMIS, INPS, TPP and Microtest, giving access to 100% of the GP systems in the UK. In addition, to meet the rapidly growing business needs, we have recruited an additional 30 staff across all aspects of the business.

In terms of our cash raising and cash deployment this year, DXS was able to reduce its issued share capital by over 3.3million shares, resulting in an improvement of over 11% in the value of each shareholder's holding in the Company.  Following this, in November 2013, we launched an entitlement and open offer for shares in DXS International plc to support the bid for Lot 1, increase our staffing and to take advantage of enhanced business prospects resulting in the issue of 3.1 million shares with no net dilution to shareholders.  The Offer was oversubscribed and we thank both our new and existing investors who have supported the Company by participating in this offer. This level of support demonstrates a significant vote of confidence in our business model and prospects.

I would particularly like to take this opportunity to thank all of our staff, and in particular the core DXS Team, for their incredible and untiring effort in delivering a superlative submission under a very demanding timetable.  This takes our Company to a new level in working for the best interests of GPSoC and the NHS. We will continue to increase the cost-effectiveness of our product for CCG's and medical practitioners and add meaningful value for shareholders in 2014 and beyond.

Finally, the audited profit for the year ending 30th April 2013 came in at £225,000, up three times on the previous year. However, for this financial year, we have the one-off cost of the GPSoC submission to contend with which has reduced profitability for the year but the benefits are already apparent with turnover up by 10% in three months since the year end.

We have already increased resources in sales, marketing, content, coding, support and training in order to deliver a first class service to our new and existing client base. These are exciting times indeed for DXS International and I look forward to the future with confidence

Bob Sutcliffe

Chairman

REPORT OF THE DIRECTORS

The directors present their annual report and the audited financial statements for the year ended 30th April 2014. The Chairman's statement which is included in this report includes a review of the achievements of the company, the trading performance, financial position and trading prospects.

Directors

The directors for the year were:

D Immelman - CEO

S Bauer - MD

B Sutcliffe - Chair

Acquisition Of Own Shares

In terms of an agreement dated 28th August 2013, the company agreed to purchase 3,360,291 ordinary shares of £0.0033 each for a total consideration of £360.

Principal Activities

The group's principal activities during the period were the development and distribution of clinical decision support to General Practitioners, Nurses and Retail Pharmacies in the United Kingdom and South Africa. The commercial side included the licensing of DXS to various CCG's, the sale of e-detailing opportunities to the pharmaceutical industry, the UK Primary Care sector and the licensing of DXS technology to healthcare publishers.

Principal Risks

Failure to achieve predicted quantities of DXS contracts and slower development of additional revenue streams may result in revenues growing more slowly than anticipated.

Financial Instruments

At this stage the Group is not faced with risk relating to interest rates on loans, credit and liquidity.

Payment of Creditors

While the Group does not follow any standard payment practice, the Group has agreed terms of payment with the majority of its creditors of 30 days. The company has actually achieved payment with the majority of its creditors of 25 days.

Dividend

The Directors do not recommend a dividend.

Research and Development

The company continues to invest into research and development both local and internationally. With the rapid emergence of Clinical Commissioning Groups in the UK healthcare sector and their requirement to achieve £20 billion of savings by 2015, the demands of CCG's for DXS to design and create new solutions to achieve this is on-going. Each newly developed product represents additional revenue streams for the company.

Directors' Responsibilities

The Directors are responsible for preparing the financial statements for each financial year. The directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

• Select suitable accounting policies and apply them consistently.
• Make judgments and accounting estimates that are reasonable and prudent.
• State whether UK accounting principles have been followed subject to any material departures  disclosed and explained in the financial statements and,
• Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in the business.

The directors are responsible for keeping proper accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company's auditors are aware of that information.

Approved by the board and signed on its behalf by:

D A Immelman
Director

20^th August 2014

CONSOLIDATED PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 30 APRIL 2014

All amounts relate to continuing activities

All recognised gains and losses are included in the profit and loss account

BALANCE SHEET
AS AT 30 APRIL 2014

Approved by the Board for issue on 20^th August 2014

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2014

1        Accounting policies

1.1     Accounting convention

The financial statements are prepared under the historical cost convention.

1.2     Compliance with accounting standards

The financial statements are prepared in accordance with applicable United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) which have been applied consistently (except as otherwise stated).

1.3     Going concern

At 30^th April 2014, the Group had net current liabilities and deferred income totalling £ (158,640) (2013 - liabilities of £ (180,347). The directors have reviewed the current 2014/15 management accounts as well as preparing a financial forecast for 2014/15 on the basis of various trading and working capital assumptions to determine the Group's funding requirements.

The Group is reliant on the continued support of certain creditors and shareholders to enable it to continue as a going concern. These creditors have given confirmations that they will not call for a payment of these debts for a period of at least twelve month from the date of the approval of these financial statements.

On the basis of the forecasting exercise and the continued availability of debtor finance the directors have concluded that the Group will be able to operate for a period of at least twelve months from the date of approval of these financial statements.

There can be no certainty that the outcome of all the matters discussed above will be as forecast by the directors, however there are no matters or events known by the directors which would preclude the adoption of the going concern basis in the preparation of these financial statements. The financial statements do not include any adjustments to the value of balance sheet assets or liabilities which would result should the going concern not be valid.

1.4     Basis of consolidation

The group financial statements consolidate those of the company and of its subsidiaries using the acquisition method of accounting. All companies within the group make up their accounts to the same date.

Results of subsidiary undertakings acquired during the financial period are included from the effective date on which control is acquired. The separate net assets of newly acquired subsidiary undertakings are incorporated into the financial statements on the basis of the fair value to the group as at the effective date.

Goodwill on consolidation is being amortised in equal instalments over its estimated useful economic life of 20 years.

1.5         Turnover 

Turnover represents amounts receivable under advertising contracts and is recognised on a straight line over the life of the contract in accordance with the substantial risks and rewards of the contract. Turnover invoiced in advance is deferred and included with current liabilities. A fair proportion of the revenue in respect of the initial contract for each customer is taken to revenue when the contract is signed.

1.6     Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Plant & equipment                                          3-4 years straight line

1.7     Intangible fixed Assets

Deferred Development expenditure is amortised over 5 years on a straight line basis from the date that the specific product is completed and is available for distribution.

The Computer software is the basis for the software development of the company.  The software is continually updated and improved. The cost of the Computer software is being amortised in equal instalments over its estimated useful economic life of 20 years.

1.8     Foreign Currency Translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rates ruling at the date of the transaction. All differences are taken to profit and loss account.

1.9     Taxation

The taxation charge in the profit and loss account is based on the taxable profits for the period at current rates of taxation and takes into account any provision for deferred taxation.

1.10   Deferred taxation

Deferred taxation is provided in full on timing differences arising from the different treatment of items for accounting and taxation purposes which are expected to reverse in the future, calculated at current tax rates, where deemed material. Deferred tax assets and liabilities are not discounted.

1.11   Research and Development

Research expenditure is written off to the profit and loss account in the year in which it is incurred. Development expenditure is written off in the same way unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period during which the company is expected to benefit.

1.12   Operating leases

Rentals payable under operating leases are charged against income on a straight line basis over the lease term.

1.13   Company Profit and Loss Account

The company has taken advantage of the exemption permitted under Section 408 of the Companies Act 2006 and has not presented its own profit and loss account in these financial statements. The company's loss after tax for the year was £454 (2013 - (loss) of £ (2,381)).

1.14   Fixed Asset Investments

Fixed asset investments are stated at cost less provision for permanent diminution in value.

The Directors confirm that the Company has complied with Guidance Note 69.1 of the ISDX Rules for Issuers throughout the period.